---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-24-000017"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:27:38.281465+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pfizer posts FY2023 revenue $58.5B, adj EPS $1.84; reaffirms FY2024 guidance

## Summary
- Full-year 2023 revenues $58.5B, down 41% operationally; reported diluted EPS $0.37, down 93%; adjusted diluted EPS $1.84, down 72%.
- Q4 2023 revenues $14.2B, down 42% operationally; reported diluted LPS $(0.60), adjusted EPS $0.10.
- Ex-COVID products grew 7% operationally in FY2023 (8% in Q4); Seagen acquisition closed Dec 2023 for $44B.
- FY2024 revenue guidance $58.5-61.5B, adj EPS $2.05-2.25; expects $4B cost savings by end 2024.
- No share repurchases planned in 2024; $9.2B dividends paid in FY2023.

## SEC filing metadata
- accession: 0000078003-24-000017
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/pfe-20240130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-24-000017
- JSON: https://secwatch.observer/filing/0000078003-24-000017.json
- Plain text: https://secwatch.observer/filing/0000078003-24-000017.txt

## Key facts
- Earnings Releases
  PFIZER INC reported full-year 2024 results: revenue $58.5 to $61.5 Billion, EPS $2.05 to $2.25. Guidance reaffirmed.
  - Period: full-year 2024
  - Revenue: $58.5 to $61.5 Billion
  - EPS: $2.05 to $2.25
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Annual Net Cost Savings by End of 2024 from Previously Announced Cost Realignment Program ▪ Reaffirms Full-Year 2024 Guidance (5) Provided on December 13, 2023, of Revenues of $58.5 to $61.5 Billion and Adjusted (3) Diluted EPS of $2.05 to $2.25 NEW YORK, Tuesday, January 30, 2024 — Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm
- Earnings Releases
  PFIZER INC reported fourth-quarter 2023 results: revenue $14.2 Billion, net income ($3,369) million, EPS ($0.60).
  - Period: fourth-quarter 2023
  - Revenue: $14.2 Billion
  - Net income: ($3,369) million
  - EPS: ($0.60)
  - Result: reported results
  source text: $0.37, Down 93% Year-Over-Year, and Adjusted (3) Diluted EPS of $1.84, Down 72% Year-Over-Year, Significantly Impacted by One-Time Events (4) ▪ Fourth-Quarter 2023 Revenues of $14.2 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove 42% Operational Decrease in Fourth-Quarter Revenues – Excluding Contributions from Comirnaty (1) and Paxlovid,
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm
- Earnings Releases
  PFIZER INC reported full-year 2023 results: revenue $58.5 Billion, net income $2,119 million, EPS $0.37.
  - Period: full-year 2023
  - Revenue: $58.5 Billion
  - Net income: $2,119 million
  - EPS: $0.37
  - Result: reported results
  source text: Launched Significant Number of New Products and Indications; and Realigned Commercial Organization to Improve Focus, Speed and Execution ▪ Full-Year 2023 Revenues of $58.5 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove 41% Operational Decrease in Year-Over-Year Revenues – Excluding Contributions from Comirnaty (1) and Paxlovid,
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.